Cyclosporine Market Outlook 2026–2035: Growth Drivers and Industry Forecast

Uncover key drivers, emerging technologies, and competitive movements shaping the cyclosporine market from 2026–2035 with trusted insights from The Business Research Company

How much is the Cyclosporine Market valued at in 2026, and what valuation is forecast for 2030?

The cyclosporine market has demonstrated significant expansion in recent years. It is projected to expand from $2.98 billion in 2025 to reach $3.37 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 13.0%. The historical growth of this market is attributable to factors such as an increase in organ transplant procedures, its established effectiveness in immune suppression, a rising prevalence of autoimmune diseases, initial regulatory approvals, and the wider adoption of hospital-based immunotherapy.

The cyclosporine market size is anticipated to exhibit rapid expansion over the next few years. It is forecast to grow to $5.46 billion by 2030, achieving a compound annual growth rate (CAGR) of 12.8%. The projected growth during this period stems from factors such as the increasing incidence of chronic autoimmune conditions, an escalating burden of ophthalmic diseases, enhanced transplant survival rates, wider availability of generic products, and the growing adoption of outpatient immunosuppressive therapy. Prominent trends for the forecast period include the expanding application in autoimmune disease management, increasing acceptance of ophthalmic cyclosporine formulations, rising demand for long-term immunosuppressive therapies, greater use in organ transplant maintenance regimens, and the proliferation of generic cyclosporine products.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23360&type=smp

What Drivers Are Influencing The Growth Of The Cyclosporine Market?

The increasing occurrence of autoimmune diseases is anticipated to boost the expansion of the cyclosporine market. Autoimmune disorders are conditions where the immune system incorrectly targets the body’s healthy cells, leading to inflammation, tissue damage, and long-term illness. This rise in autoimmune disease cases is due to genetic predisposition, as improvements in genetic testing have identified more people with inherited risks, making them more vulnerable to these conditions. Cyclosporine works against autoimmune diseases by inhibiting T-cell activation, thus lessening detrimental immune responses against healthy tissues in illnesses like rheumatoid arthritis, psoriasis, and lupus. For example, in October 2024, a thorough review from Signal Transduction and Targeted Therapy, a journal published by Nature, a UK-based peer-reviewed scientific publisher, revealed that roughly 8.4 million patients globally are affected by rheumatoid arthritis, with its overall incidence rate rising by 2-3% annually; using the Markov model approach, the affected populations are projected to be about 13.5-17.4 million by 2040. Consequently, the rising incidence of autoimmune diseases is fueling the growth of the cyclosporine market.

How Is The Cyclosporine Market Organized Into Various Segments?

The cyclosporine market covered in this report is segmented –

1) By Indication: Transplant Rejection Prophylaxis, Rheumatoid Arthritis, Psoriasis, Autoimmune Myasthenia Gravis, Dry Eye, Other Indications

2) By Dosage Form: Capsule, Eye Drops, Liquid Solutions, Creams And Ointments

3) By Route Of Administration: Oral, Topical, Parenteral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-Users: Hospitals, Homecare, Speciality Centres, Other End-Users

Subsegments:

1) By Transplant Rejection Prophylaxis: Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant, Other Transplants

2) By Rheumatoid Arthritis: Moderate Rheumatoid Arthritis, Severe Rheumatoid Arthritis

3) By Psoriasis: Plaque Psoriasis, Erythrodermic Psoriasis, Guttate Psoriasis, Pustular Psoriasis

4) By Autoimmune Myasthenia Gravis: Generalized Myasthenia Gravis, Ocular Myasthenia Gravis

5) By Dry Eye: Chronic Dry Eye, Severe Dry Eye

6) By Other Indications: Atopic Dermatitis, Uveitis, Nephrotic Syndrome, Inflammatory Bowel Disease (IBD)

Which Trends Are Shaping Activity Within The Cyclosporine Market?

Major companies operating in the cyclosporine market are primarily focused on acquiring regulatory approvals to expand their product portfolios and boost their market presence. Such regulatory endorsements for cyclosporine confirm its safety and efficacy, allowing for market entry and building confidence among prescribers and patients. For instance, in June 2023, Novaliq GmbH, a Germany-based biopharmaceutical company, secured approval from the U.S. FDA for VEVYE (cyclosporine ophthalmic solution) 0.1%, a unique water-free ophthalmic medication designed for the treatment of dry eye disease (DED). This represents the first and only cyclosporine-based solution for this condition, demonstrating its effectiveness in just four weeks. VEVYE incorporates an innovative water-free technology called EyeSol, which improves cyclosporine’s bioavailability and its retention time on the ocular surface without requiring preservatives, oils, or surfactants. The solution acts as a calcineurin inhibitor, helping to diminish inflammation associated with dry eye disease.

Who Are The Top-Performing Companies In The Cyclosporine Market In Recent Years?

Major companies operating in the cyclosporine market are Novartis AG, Viatris Inc., Teva Pharmaceutical Industries Ltd, Sandoz International GmbH, Sun Pharmaceutical Industries Ltd, Apotex Inc., Cipla Ltd, Dr. Reddy’s Laboratories Ltd, Lupin Limited, Glenmark Pharmaceuticals Ltd, Taj Pharmaceuticals Limited, Panacea Biotec Ltd, Novaliq GmbH, Simson Pharma Limited, Strides Pharma Science Ltd, AdvaCare Pharma, JoinHub Pharma, Grevis Pharmaceuticals Pvt Ltd, GMT Pharma International, Logos Pharma.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/cyclosporine-global-market-report

Which Region Currently Holds The Largest Share Of The Cyclosporine Market?

Asia-Pacific was the largest region in the cyclosporine market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the cyclosporine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Cyclosporine Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23360&type=smp

Browse Through More Reports Similar to the Global Cyclosporine Market 2026, By The Business Research Company

Interstitial Cystitis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/interstitial-cystitis-drugs-global-market-report

Cyclohexylbenzene Market Report 2026

https://www.thebusinessresearchcompany.com/report/cyclohexylbenzene-global-market-report

Cyclin Dependent Kinase Cdk 4 Or 6 Inhibitor Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/cyclin-dependent-kinase-cdk-4-or-6-inhibitor-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795